Fundraiser

Fundraiser Image
Courageous Charlie Blend can be purchased: Click Here
Fundraiser Information:
  1. Start Date: March 25, 2021
  2. End Date: May 31, 2021
  3. $12 from every Courageous Charlie Blend bag sold will be donated to the The Leukemia & Lymphoma Society (LLS).
Charlie's Parents:
  1. Charlie is the best thing to ever happen to us. Since birth, he has opened more minds and touched more hearts than all of my years combined. We were prepared for Charlie to have Down syndrome at birth but were not prepared for his serious blood disorder, Transient Myeloproliferative Disorder (TMD), a condition that occurs in 5-10% of Down syndrome babies. Despite his strong, healthy body, initially resolving the blood disorder for months, we received his diagnosis of Acute Myeloid Leukemia. From the very start of Charlie's journey, extraordinary people have come into our lives the moment we needed them. A good friend and Mom's In Training (MIT) coach, who had lost her father to an aggressive form of cancer, encouraged me to join MIT. When she told me MIT was a group of moms supporting The Leukemia and Lymphoma Society (LLS), a bell went off in my head. My son's blood disorder had just recently begun to show signs of returning, and the phrase "25% risk for childhood leukemia" was blazing in my mind. Two weeks later, Charlie needed a bone marrow aspiration, and as I anxiously awaited the test results, I attended the MIT kickoff. Because of the LLS community, I'm starting this journey from a strong place, 180 degrees from facing it alone.

    Christy Allen, Charlie's mom
Charity Information:
  1. From the start of 2017 until today, the U.S. Food and Drug Administration (FDA) has approved an incredible 54 blood cancer treatments. What's more is The Leukemia & Lymphoma Society (LLS) helped advance 47 of those treatments at some point in their development journey.
  2. In the past 70 years, LLS has invested $1.3 billion into the most cutting edge and promising research.
  3. Blood cancers account for more than 40 percent of all childhood cancers. Leukemia is the most common pediatric cancer and lymphoma the third. Most children are treated with chemotherapies developed in the 1950s and 1960s; they are harsh and outdated and simply do not work well enough. Too many young patients succumb to their cancer. For those who do survive, treatments can cause severe and permanent physical and cognitive impairments and secondary illnesses and cancers. Approximately 80% of childhood cancer survivors develop chronic health conditions, such as heart disease and cognitive impairments, as a result of their treatment.
  4. Only 4 oncology drugs have been approved for first use in children in 40 years.
  5. We believe blood cancer is curable. That is the simple, singular inspiration of LLS. Today, with the incredible opportunities of the precision medicine revolution, we are focusing our leadership and expertise on the urgent needs of children. By taking the opportunities and promise of the genomic age and applying a child-focused vision, we seek to transform precision medicine from a scientific revolution into revolutionary cures for pediatric patients.
  6. LLS is more than doubling its investment in pediatric research grants to advance promising, high-impact science with a clear bench-to-bedside trajectory. We are reimagining childhood cancer cures.
  7. The needs of children with blood cancer are unique; the therapies used to cure them should be unique as well. That is the power of precision medicine. Our goal is a future in which treatments target a child's specific genomics to kill the cancer and leave healthy cells unharmed.

 

fundraiser goal

Amount Raised